Complement Activation during Critical Illness: Current Findings and an Outlook in the Era of COVID-19

被引：13

作者：

Bosmann, Markus ^{[1
,2
]}

机构：

[1] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA

[2] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Ctr Thrombosis & Hemostasis, Mainz, Germany

来源：

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2020年 / 202卷 / 02期

关键词：

D O I：

10.1164/rccm.202005-1926ED

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

引用

页码：163 / 165

页数：4

共 14 条

[1] Increased Alternative Complement Pathway Function and Improved Survival during Critical Illness [J].

Bain, William ;

Li, Huihua ;

van der Geest, Rick ;

Moore, Sara R. ;

Olonisakin, Tolani F. ;

Ahn, Brian ;

Papke, Erin ;

Moghbeli, Kaveh ;

DeSensi, Rebecca ;

Rapport, Sarah ;

Saul, Melissa ;

Hulver, Mei ;

Xiong, Zeyu ;

Mallampalli, Rama K. ;

Ray, Prabir ;

Morris, Alison ;

Ma, Lina ;

Doi, Yohei ;

Zhang, Yingze ;

Kitsios, Georgios D. ;

Kulkarni, Hrishikesh S. ;

McVerry, Bryan J. ;

Ferreira, Viviana P. ;

Nouraie, Mehdi ;

Lee, Janet S. .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 202 (02) :230-240

[2]

Blanco-Melo D., 2020, SARS COV 2 LAUNCHES

[3] Role of C3, C5 and Anaphylatoxin Receptors in Acute Lung Injury and in Sepsis [J].

Bosmann, Markus ;

Ward, Peter A. .

CURRENT TOPICS IN INNATE IMMUNITY II, 2012, 946 :147-159

[4] Will Complement Inhibition Be the New Target in Treating COVID-19-Related Systemic Thrombosis? [J].

Campbell, Courtney M. ;

Kahwash, Rami .

CIRCULATION, 2020, 141 (22) :1739-1741

[5] Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis [J].

Gralinski, Lisa E. ;

Sheahan, Timothy P. ;

Morrison, Thomas E. ;

Menachery, Vineet D. ;

Jensen, Kara ;

Leist, Sarah R. ;

Whitmore, Alan ;

Heise, Mark T. ;

Baric, Ralph S. .

MBIO, 2018, 9 (05)

[6] Blockade of the C5a-C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV [J].

Jiang, Yuting ;

Zhao, Guangyu ;

Song, Nianping ;

Li, Pei ;

Chen, Yuehong ;

Guo, Yan ;

Li, Junfeng ;

Du, Lanying ;

Jiang, Shibo ;

Guo, Renfeng ;

Sun, Shihui ;

Zhou, Yusen .

EMERGING MICROBES & INFECTIONS, 2018, 7

[7] Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival [J].

Kelly, Richard J. ;

Hill, Anita ;

Arnold, Louise M. ;

Brooksbank, Gemma L. ;

Richards, Stephen J. ;

Cullen, Matthew ;

Mitchell, Lindsay D. ;

Cohen, Dena R. ;

Gregory, Walter M. ;

Hillmen, Peter .

BLOOD, 2011, 117 (25) :6786-6792

[8]

Magro C, 2020, TRANSL RES, DOI [10.1016/j.trsl.2020.04.007-0., DOI 10.1016/J.TRSL.2020.04.007-0.]

[9] The first case of COVID-19 treated with the complement C3 inhibitor AMY-101 [J].

Mastaglio, Sara ;

Ruggeri, Annalisa ;

Risitano, Antonio M. ;

Angelillo, Piera ;

Yancopoulou, Despina ;

Mastellos, Dimitrios C. ;

Huber-Lang, Markus ;

Piemontese, Simona ;

Assanelli, Andrea ;

Garlanda, Cecilia ;

Lambris, John D. ;

Ciceri, Fabio .

CLINICAL IMMUNOLOGY, 2020, 215

[10] Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder [J].

Pittock, S. J. ;

Berthele, A. ;

Fujihara, K. ;

Kim, H. J. ;

Levy, M. ;

Palace, J. ;

Nakashima, I. ;

Terzi, M. ;

Totolyan, N. ;

Viswanathan, S. ;

Wang, K. -C. ;

Pace, A. ;

Fujita, K. P. ;

Armstrong, R. ;

Wingerchuk, D. M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (07) :614-625

← 1 2 →